The Amal Lab uses advanced omics technologies combined with bioinformatics, pharmacological, biochemical, biological, and behavioral methods to study autism spectrum disorder (ASD), Alzheimer's disease (AD) and other neurological disorders. The ultimate goal is to understand the molecular mechanisms and discover novel therapeutic targets for ASD, AD, and other neurological disorders. Further, the Amal lab is interested in the role of nitric oxide (NO), S-nitrosylation (the NO–mediated posttranslational modification (PTM)), and phosphorylation in these disorders.  The Amal Lab uses both clinical samples as well as transgenic mouse models. They combine proteomics, bioinformatics, biochemistry, pharmacological interventions and large set of behavioral tests.